A single blood test could detect 50+ cancers - including #LungCancer.
New #ESMO2025 data suggest stronger performance than earlier trials – possibly detecting more than 50% of true cases.
The NHS Galleri trial with 140K people will show what this means for cancers like ALK+.
#ALKPositive #LCSM
New #ESMO2025 data suggest stronger performance than earlier trials – possibly detecting more than 50% of true cases.
The NHS Galleri trial with 140K people will show what this means for cancers like ALK+.
#ALKPositive #LCSM
October 12, 2025 at 8:20 PM
A single blood test could detect 50+ cancers - including #LungCancer.
New #ESMO2025 data suggest stronger performance than earlier trials – possibly detecting more than 50% of true cases.
The NHS Galleri trial with 140K people will show what this means for cancers like ALK+.
#ALKPositive #LCSM
New #ESMO2025 data suggest stronger performance than earlier trials – possibly detecting more than 50% of true cases.
The NHS Galleri trial with 140K people will show what this means for cancers like ALK+.
#ALKPositive #LCSM
Important & moving words from our amazing Fundraising Trustee Callum, who lost his mum to ALK+ #lungcancer last March.
This September, he’s running 6 marathons in 6 days across 6 countries to raise global awareness for ALK+ lung cancer.
#ALKpositive #LungCancerAwareness #LCSM
This September, he’s running 6 marathons in 6 days across 6 countries to raise global awareness for ALK+ lung cancer.
#ALKpositive #LungCancerAwareness #LCSM
March 22, 2025 at 8:58 AM
Important & moving words from our amazing Fundraising Trustee Callum, who lost his mum to ALK+ #lungcancer last March.
This September, he’s running 6 marathons in 6 days across 6 countries to raise global awareness for ALK+ lung cancer.
#ALKpositive #LungCancerAwareness #LCSM
This September, he’s running 6 marathons in 6 days across 6 countries to raise global awareness for ALK+ lung cancer.
#ALKpositive #LungCancerAwareness #LCSM
New study shows Brigatinib still works after Crizotinib in #ALKpositive #lungcancer but only if ALK is still driving the cancer. It didn’t work when resistance came from EGFR, KRAS, MET or BRAF. Full paper 👉 www.clinical-lung-cancer.com/article/S152... #LCSM
June 8, 2025 at 7:59 AM
New study shows Brigatinib still works after Crizotinib in #ALKpositive #lungcancer but only if ALK is still driving the cancer. It didn’t work when resistance came from EGFR, KRAS, MET or BRAF. Full paper 👉 www.clinical-lung-cancer.com/article/S152... #LCSM
Scotland has confirmed routine NHS access to lorlatinib after previous ALK+ lung cancer treatment.
It had been available on an interim basis since 2020. Following reassessment and further evidence, that access is now routine.
#ALKPositive #LungCancer #LCSM
It had been available on an interim basis since 2020. Following reassessment and further evidence, that access is now routine.
#ALKPositive #LungCancer #LCSM
September 9, 2026 at 10:37 AM
Scotland has confirmed routine NHS access to lorlatinib after previous ALK+ lung cancer treatment.
It had been available on an interim basis since 2020. Following reassessment and further evidence, that access is now routine.
#ALKPositive #LungCancer #LCSM
It had been available on an interim basis since 2020. Following reassessment and further evidence, that access is now routine.
#ALKPositive #LungCancer #LCSM
Early ESMO data show neladalkib (Nuvalent) achieved a 44% response rate in ALK+ cancers beyond #lungcancer.
Still early, but it hints at strong CNS activity and tolerability. NSCLC results expected later this year.
#ALKpositive #LCSM #ESMO25
Still early, but it hints at strong CNS activity and tolerability. NSCLC results expected later this year.
#ALKpositive #LCSM #ESMO25
October 19, 2025 at 7:01 PM
Early ESMO data show neladalkib (Nuvalent) achieved a 44% response rate in ALK+ cancers beyond #lungcancer.
Still early, but it hints at strong CNS activity and tolerability. NSCLC results expected later this year.
#ALKpositive #LCSM #ESMO25
Still early, but it hints at strong CNS activity and tolerability. NSCLC results expected later this year.
#ALKpositive #LCSM #ESMO25
🌍 The 2025 ALK+ Summit brought together our community from 30 countries — united in one mission: accelerating research and supporting ALK-positive lives.
💙 Together, we are stronger.
👉 Stay connected for ALK Summit 2026: mailchi.mp/alkpositive/...
#ALKPositive #StrongerTogether
💙 Together, we are stronger.
👉 Stay connected for ALK Summit 2026: mailchi.mp/alkpositive/...
#ALKPositive #StrongerTogether
September 16, 2025 at 6:20 PM
🌍 The 2025 ALK+ Summit brought together our community from 30 countries — united in one mission: accelerating research and supporting ALK-positive lives.
💙 Together, we are stronger.
👉 Stay connected for ALK Summit 2026: mailchi.mp/alkpositive/...
#ALKPositive #StrongerTogether
💙 Together, we are stronger.
👉 Stay connected for ALK Summit 2026: mailchi.mp/alkpositive/...
#ALKPositive #StrongerTogether
A great expert review on ALK+ #lungcancer - testing, treatment, resistance, & what’s next. A solid overview of where things stand.
#ALKpositive #LCSM
acsjournals.onlinelibrary.wiley.com/doi/epdf/10....
#ALKpositive #LCSM
acsjournals.onlinelibrary.wiley.com/doi/epdf/10....
April 13, 2025 at 10:22 AM
A great expert review on ALK+ #lungcancer - testing, treatment, resistance, & what’s next. A solid overview of where things stand.
#ALKpositive #LCSM
acsjournals.onlinelibrary.wiley.com/doi/epdf/10....
#ALKpositive #LCSM
acsjournals.onlinelibrary.wiley.com/doi/epdf/10....
Blood clots are killing ALK+ #lungcancer patients faster - yet risk isn’t being systematically assessed. New research shows 1 in 3 develop VTE.
Survival drops from 76 to 25 months.
This needs to change. 🔴 jtocrr.org/article/S2666-3643(26)00054-8/fulltext #ALKpositive #LCSM
Survival drops from 76 to 25 months.
This needs to change. 🔴 jtocrr.org/article/S2666-3643(26)00054-8/fulltext #ALKpositive #LCSM
April 26, 2026 at 4:34 PM
Blood clots are killing ALK+ #lungcancer patients faster - yet risk isn’t being systematically assessed. New research shows 1 in 3 develop VTE.
Survival drops from 76 to 25 months.
This needs to change. 🔴 jtocrr.org/article/S2666-3643(26)00054-8/fulltext #ALKpositive #LCSM
Survival drops from 76 to 25 months.
This needs to change. 🔴 jtocrr.org/article/S2666-3643(26)00054-8/fulltext #ALKpositive #LCSM
New research is helping us understand why ALK targeted treatments can stop working.
In 148 people with ALK+ #lungcancer, researchers identified changes in the RAS pathway as one possible route of resistance.
An important clue for future research.
#ALKPositive #LungCancer #LCSM
In 148 people with ALK+ #lungcancer, researchers identified changes in the RAS pathway as one possible route of resistance.
An important clue for future research.
#ALKPositive #LungCancer #LCSM
September 3, 2026 at 7:57 AM
New research is helping us understand why ALK targeted treatments can stop working.
In 148 people with ALK+ #lungcancer, researchers identified changes in the RAS pathway as one possible route of resistance.
An important clue for future research.
#ALKPositive #LungCancer #LCSM
In 148 people with ALK+ #lungcancer, researchers identified changes in the RAS pathway as one possible route of resistance.
An important clue for future research.
#ALKPositive #LungCancer #LCSM
New Case report: SMARCA4-deficient NSCLC with ALK fusion.
Applied Immunohistochemistry & Molecular Morphology describes a rare & interesting case - a non-smoking woman with non-small cell #lungcancer that was SMARCA4-deficient, yet still harboured an ALK fusion.
#ALKPositive #LCSM
Applied Immunohistochemistry & Molecular Morphology describes a rare & interesting case - a non-smoking woman with non-small cell #lungcancer that was SMARCA4-deficient, yet still harboured an ALK fusion.
#ALKPositive #LCSM
October 11, 2025 at 9:52 PM
New Case report: SMARCA4-deficient NSCLC with ALK fusion.
Applied Immunohistochemistry & Molecular Morphology describes a rare & interesting case - a non-smoking woman with non-small cell #lungcancer that was SMARCA4-deficient, yet still harboured an ALK fusion.
#ALKPositive #LCSM
Applied Immunohistochemistry & Molecular Morphology describes a rare & interesting case - a non-smoking woman with non-small cell #lungcancer that was SMARCA4-deficient, yet still harboured an ALK fusion.
#ALKPositive #LCSM
Jarushka Naidoo Shares Duncan Preece’s Patient-Focused Insights from ALK Positive Canada
@drjnaidoo.bsky.social
oncodaily.com/blog/jarushk...
#ALKPositive #Cancer #LungHealthCheckIreland #OncoDaily #Oncology
@drjnaidoo.bsky.social
oncodaily.com/blog/jarushk...
#ALKPositive #Cancer #LungHealthCheckIreland #OncoDaily #Oncology
Jarushka Naidoo Shares Duncan Preece’s Patient-Focused Insights from ALK Positive Canada - OncoDaily
Jarushka Naidoo Shares Duncan Preece’s Patient-Focused Insights from ALK Positive Canada / ALK Positive, cancer, Duncan Preece, Jarushka Naidoo, Lung Health
oncodaily.com
June 22, 2025 at 5:30 PM
Jarushka Naidoo Shares Duncan Preece’s Patient-Focused Insights from ALK Positive Canada
@drjnaidoo.bsky.social
oncodaily.com/blog/jarushk...
#ALKPositive #Cancer #LungHealthCheckIreland #OncoDaily #Oncology
@drjnaidoo.bsky.social
oncodaily.com/blog/jarushk...
#ALKPositive #Cancer #LungHealthCheckIreland #OncoDaily #Oncology
Hello, Bluesky!
We’re ALK Positive, a patient-driven nonprofit dedicated to improving the lives of those impacted by ALK-positive cancers. We’re thrilled to join this community and connect with individuals passionate about making a difference. 💙
#LungCancerAwareness #ALKPositive #LCAM2024
We’re ALK Positive, a patient-driven nonprofit dedicated to improving the lives of those impacted by ALK-positive cancers. We’re thrilled to join this community and connect with individuals passionate about making a difference. 💙
#LungCancerAwareness #ALKPositive #LCAM2024
November 26, 2024 at 12:33 AM
Hello, Bluesky!
We’re ALK Positive, a patient-driven nonprofit dedicated to improving the lives of those impacted by ALK-positive cancers. We’re thrilled to join this community and connect with individuals passionate about making a difference. 💙
#LungCancerAwareness #ALKPositive #LCAM2024
We’re ALK Positive, a patient-driven nonprofit dedicated to improving the lives of those impacted by ALK-positive cancers. We’re thrilled to join this community and connect with individuals passionate about making a difference. 💙
#LungCancerAwareness #ALKPositive #LCAM2024
Becca, who has stage 4 ALK+ #lungcancer, spoke on BBC Morning Live ahead of Lung Cancer Awareness Month 💙
Diagnosed nearly six years ago after back pain and vision problems, she’s helping challenge outdated ideas about who can get lung cancer.
#LungCancerAwarenessMonth #ALKPositive #LCSM
Diagnosed nearly six years ago after back pain and vision problems, she’s helping challenge outdated ideas about who can get lung cancer.
#LungCancerAwarenessMonth #ALKPositive #LCSM
October 31, 2025 at 8:35 AM
Becca, who has stage 4 ALK+ #lungcancer, spoke on BBC Morning Live ahead of Lung Cancer Awareness Month 💙
Diagnosed nearly six years ago after back pain and vision problems, she’s helping challenge outdated ideas about who can get lung cancer.
#LungCancerAwarenessMonth #ALKPositive #LCSM
Diagnosed nearly six years ago after back pain and vision problems, she’s helping challenge outdated ideas about who can get lung cancer.
#LungCancerAwarenessMonth #ALKPositive #LCSM
💡5-Year Update: Lorlatinib vs. Crizotinib in 1L ALK+ NSCLC! 🎗️
The long-term follow-up data from the Phase 3 CROWN study, @ascocancer.bsky.social, reveals unprecedented outcomes for lorlatinib in previously untreated, advanced ALK+ NSCLC.
#Onco404 #Cancer #Oncology #LungCancer #ALKpositive
The long-term follow-up data from the Phase 3 CROWN study, @ascocancer.bsky.social, reveals unprecedented outcomes for lorlatinib in previously untreated, advanced ALK+ NSCLC.
#Onco404 #Cancer #Oncology #LungCancer #ALKpositive
March 27, 2025 at 8:35 AM
💡5-Year Update: Lorlatinib vs. Crizotinib in 1L ALK+ NSCLC! 🎗️
The long-term follow-up data from the Phase 3 CROWN study, @ascocancer.bsky.social, reveals unprecedented outcomes for lorlatinib in previously untreated, advanced ALK+ NSCLC.
#Onco404 #Cancer #Oncology #LungCancer #ALKpositive
The long-term follow-up data from the Phase 3 CROWN study, @ascocancer.bsky.social, reveals unprecedented outcomes for lorlatinib in previously untreated, advanced ALK+ NSCLC.
#Onco404 #Cancer #Oncology #LungCancer #ALKpositive
Brenda’s symptoms—brain fog, tiredness, & vision issues—seemed vague & not serious. By mid-2023, she was diagnosed with Stage 4 ALK+ lung cancer. Less than a year later, she passed away. Her story shows how subtle #lungcancer signs can be. If something feels off, speak to your GP. #ALKPositive #LCSM
December 7, 2024 at 8:05 AM
Brenda’s symptoms—brain fog, tiredness, & vision issues—seemed vague & not serious. By mid-2023, she was diagnosed with Stage 4 ALK+ lung cancer. Less than a year later, she passed away. Her story shows how subtle #lungcancer signs can be. If something feels off, speak to your GP. #ALKPositive #LCSM
The latest @iaslc.bsky.social Lung Cancer Considered podcast with @stephenvliu.bsky.social looks at treatment for Stage 3 ALK+ #lungcancer. This episode looks at a real case & the key decisions around treatment & molecular testing.
🎧 Listen here: www.iaslc.org/iaslc-news/l...
#LSCM #ALKPositive
🎧 Listen here: www.iaslc.org/iaslc-news/l...
#LSCM #ALKPositive
Virtual Tumor Board: Stage III ALK+ NSCLC | IASLC
This IASLC Virtual Tumor Board episode focuses on a patient with stage III ALK-positive NSCLC. ALK fusions are present in about 5% of NSCLC and there are now si ...
www.iaslc.org
March 19, 2025 at 10:26 PM
The latest @iaslc.bsky.social Lung Cancer Considered podcast with @stephenvliu.bsky.social looks at treatment for Stage 3 ALK+ #lungcancer. This episode looks at a real case & the key decisions around treatment & molecular testing.
🎧 Listen here: www.iaslc.org/iaslc-news/l...
#LSCM #ALKPositive
🎧 Listen here: www.iaslc.org/iaslc-news/l...
#LSCM #ALKPositive
Honored to join the @IASLC Lung Cancer Considered Podcast highlighting the 2025 ALK+ Summit. 🎧 Hear our board members share how advocacy & community shape the future of ALK+ research.
🔗 soundcloud.com/lungcancerco...
#ALKPositive #LungCancer #PatientAdvocacy
🔗 soundcloud.com/lungcancerco...
#ALKPositive #LungCancer #PatientAdvocacy
August 27, 2025 at 4:35 PM
Honored to join the @IASLC Lung Cancer Considered Podcast highlighting the 2025 ALK+ Summit. 🎧 Hear our board members share how advocacy & community shape the future of ALK+ research.
🔗 soundcloud.com/lungcancerco...
#ALKPositive #LungCancer #PatientAdvocacy
🔗 soundcloud.com/lungcancerco...
#ALKPositive #LungCancer #PatientAdvocacy
🚨 SOLD OUT! 🚨
The 2025 ALK+ Summit in San Diego is officially SOLD OUT for in-person attendance! 🎉
💻 Missed out? Join us virtually!
➡️ Want an in-person spot? Join the waitlist!
🔗 Register & waitlist here: secure.qgiv.com/for/alksummit2025/event/2025alksummit/
💙 #ALKPositive #ALKSummit2025
The 2025 ALK+ Summit in San Diego is officially SOLD OUT for in-person attendance! 🎉
💻 Missed out? Join us virtually!
➡️ Want an in-person spot? Join the waitlist!
🔗 Register & waitlist here: secure.qgiv.com/for/alksummit2025/event/2025alksummit/
💙 #ALKPositive #ALKSummit2025
March 13, 2025 at 12:40 PM
🚨 SOLD OUT! 🚨
The 2025 ALK+ Summit in San Diego is officially SOLD OUT for in-person attendance! 🎉
💻 Missed out? Join us virtually!
➡️ Want an in-person spot? Join the waitlist!
🔗 Register & waitlist here: secure.qgiv.com/for/alksummit2025/event/2025alksummit/
💙 #ALKPositive #ALKSummit2025
The 2025 ALK+ Summit in San Diego is officially SOLD OUT for in-person attendance! 🎉
💻 Missed out? Join us virtually!
➡️ Want an in-person spot? Join the waitlist!
🔗 Register & waitlist here: secure.qgiv.com/for/alksummit2025/event/2025alksummit/
💙 #ALKPositive #ALKSummit2025
The ALKnowledge is now live.
Created by experts and shaped by patient insights from ALK Positive UK, with clear, information about this form of non-small cell lung cancer and its fast-evolving treatment landscape. alknowledge.org
#LifeEnhancingEducation #CancerCare #ALKPositive #LungCancer
Created by experts and shaped by patient insights from ALK Positive UK, with clear, information about this form of non-small cell lung cancer and its fast-evolving treatment landscape. alknowledge.org
#LifeEnhancingEducation #CancerCare #ALKPositive #LungCancer
May 1, 2025 at 2:58 PM
The ALKnowledge is now live.
Created by experts and shaped by patient insights from ALK Positive UK, with clear, information about this form of non-small cell lung cancer and its fast-evolving treatment landscape. alknowledge.org
#LifeEnhancingEducation #CancerCare #ALKPositive #LungCancer
Created by experts and shaped by patient insights from ALK Positive UK, with clear, information about this form of non-small cell lung cancer and its fast-evolving treatment landscape. alknowledge.org
#LifeEnhancingEducation #CancerCare #ALKPositive #LungCancer
I had an appointment with my oncologist to go over my 12 week scans. He said the cancer spots are either stable, shrinking, and some smaller spots have even disappeared. My numbers look good and I'm tolerating the medication fine. Good day today. #CancerSky #ALKPositive #LungCancer
a close up of a sloth sleeping in a wicker chair with memepix.com in the corner
Alt: a close up of a sloth sleeping in a wicker chair with memepix.com in the corner
media.tenor.com
January 30, 2025 at 6:12 AM
I had an appointment with my oncologist to go over my 12 week scans. He said the cancer spots are either stable, shrinking, and some smaller spots have even disappeared. My numbers look good and I'm tolerating the medication fine. Good day today. #CancerSky #ALKPositive #LungCancer
Applying Complexity Science to Terminal Illness.
Hypothesis: "Détente" is more resiliant than "War."
Method: 4th-Gen TKIs + Psychoneuroimmunology.
Result: Sclerotic containment & BBB repair.
#LungCancer #ALKpositive #Epigenetics #DeepakChopra #MayimBialik #JamesGlattfelder #SciComm #Stoicism
Hypothesis: "Détente" is more resiliant than "War."
Method: 4th-Gen TKIs + Psychoneuroimmunology.
Result: Sclerotic containment & BBB repair.
#LungCancer #ALKpositive #Epigenetics #DeepakChopra #MayimBialik #JamesGlattfelder #SciComm #Stoicism
The Diamond Standard: An N-of-1 Experiment in Co-Existing with Terminal Illness
Beyond the "War on Cancer"—Mapping the Intersection of Fourth-Generation TKI Therapy and the Harmonist Mindset.
open.substack.com
December 2, 2025 at 5:04 AM
Applying Complexity Science to Terminal Illness.
Hypothesis: "Détente" is more resiliant than "War."
Method: 4th-Gen TKIs + Psychoneuroimmunology.
Result: Sclerotic containment & BBB repair.
#LungCancer #ALKpositive #Epigenetics #DeepakChopra #MayimBialik #JamesGlattfelder #SciComm #Stoicism
Hypothesis: "Détente" is more resiliant than "War."
Method: 4th-Gen TKIs + Psychoneuroimmunology.
Result: Sclerotic containment & BBB repair.
#LungCancer #ALKpositive #Epigenetics #DeepakChopra #MayimBialik #JamesGlattfelder #SciComm #Stoicism
Amy, Seth, Amanda & Nancy are powered by faith, family & the fight for more research.
This #ALKPositive Awareness Month, they’re taking action to raise $500K for lifesaving breakthroughs.
Join the #PoweredByPatients movement 👉 secure.qgiv.com/event/alkpos... #APAM
This #ALKPositive Awareness Month, they’re taking action to raise $500K for lifesaving breakthroughs.
Join the #PoweredByPatients movement 👉 secure.qgiv.com/event/alkpos... #APAM
June 16, 2025 at 2:45 PM
Amy, Seth, Amanda & Nancy are powered by faith, family & the fight for more research.
This #ALKPositive Awareness Month, they’re taking action to raise $500K for lifesaving breakthroughs.
Join the #PoweredByPatients movement 👉 secure.qgiv.com/event/alkpos... #APAM
This #ALKPositive Awareness Month, they’re taking action to raise $500K for lifesaving breakthroughs.
Join the #PoweredByPatients movement 👉 secure.qgiv.com/event/alkpos... #APAM
Could alectinib be used before surgery for ALK+ #lungcancer?
In the phase 2 NAUTIKA1 study, 55.8% had a major pathological response after 8 weeks of alectinib before surgery.
It’s early research, but an interesting new direction for ALK+ treatment.
#WCLC26 #ALKPositive #LCSM
In the phase 2 NAUTIKA1 study, 55.8% had a major pathological response after 8 weeks of alectinib before surgery.
It’s early research, but an interesting new direction for ALK+ treatment.
#WCLC26 #ALKPositive #LCSM
September 17, 2026 at 8:04 AM
Could alectinib be used before surgery for ALK+ #lungcancer?
In the phase 2 NAUTIKA1 study, 55.8% had a major pathological response after 8 weeks of alectinib before surgery.
It’s early research, but an interesting new direction for ALK+ treatment.
#WCLC26 #ALKPositive #LCSM
In the phase 2 NAUTIKA1 study, 55.8% had a major pathological response after 8 weeks of alectinib before surgery.
It’s early research, but an interesting new direction for ALK+ treatment.
#WCLC26 #ALKPositive #LCSM
Are we heading towards combo treatment in #ALKPositive #lungcancer?
Alectinib + bevacizumab showed “durable disease control” at 3 years in the ALEK-B trial, just published in Nature Communications
Raises new questions about how to delay resistance.
🔗 www.nature.com/articles/s41...
#NSCLC #LCSM
Alectinib + bevacizumab showed “durable disease control” at 3 years in the ALEK-B trial, just published in Nature Communications
Raises new questions about how to delay resistance.
🔗 www.nature.com/articles/s41...
#NSCLC #LCSM
Alectinib in combination with bevacizumab as first-line treatment in ALK-rearranged non-small cell lung cancer (ALEK-B): a single-arm, phase 2 trial - Nature Communications
Up to 25% of patients with ALK-rearranged non-small cell lung cancer (NSCLC) experience disease progression within the first year of targeted therapy. This work reports a phase 2 trial investigating w...
www.nature.com
May 18, 2025 at 9:34 AM
Are we heading towards combo treatment in #ALKPositive #lungcancer?
Alectinib + bevacizumab showed “durable disease control” at 3 years in the ALEK-B trial, just published in Nature Communications
Raises new questions about how to delay resistance.
🔗 www.nature.com/articles/s41...
#NSCLC #LCSM
Alectinib + bevacizumab showed “durable disease control” at 3 years in the ALEK-B trial, just published in Nature Communications
Raises new questions about how to delay resistance.
🔗 www.nature.com/articles/s41...
#NSCLC #LCSM